File(s) stored somewhere else

Please note: Linked content is NOT stored on University of Illinois at Chicago and we can't guarantee its availability, quality, security or accept any liability.

Pregnancy outcomes among women receiving RVSVΔ-Zebov-GP Ebola vaccine during the Sierra Leone trial to introduce a vaccine against Ebola

journal contribution
posted on 10.06.2021, 17:40 by JK Legardy-Williams, RJ Carter, ST Goldstein, Olamide JarrettOlamide Jarrett, E Szefer, AE Fombah, SC Tinker, M Samai, BE Mahon
Little information exists regarding Ebola vaccine rVSVΔGZEBOV-GP and pregnancy. The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) randomized participants without blinding to immediate or deferred (18-24 weeks postenrollment) vaccination. Pregnancy was an exclusion criterion, but 84 women were inadvertently vaccinated in early pregnancy or became pregnant <60 days after vaccination or enrollment. Among immediate vaccinated women, 45% (14/31) reported pregnancy loss, compared with 33% (11/33) of unvaccinated women with contemporaneous pregnancies (relative risk 1.35, 95% CI 0.73-2.52). Pregnancy loss was similar among women with higher risk for vaccine viremia (conception before or <14 days after vaccination) (44% [4/9]) and women with lower risk (conception >15 days after vaccination) (45% [10/22]). No congenital anomalies were detected among 44 live-born infants examined. These data highlight the need for Ebola vaccination decisions to balance the possible risk for an adverse pregnancy outcome with the risk for Ebola exposure.

History

Citation

Legardy-Williams, J. K., Carter, R. J., Goldstein, S. T., Jarrett, O. D., Szefer, E., Fombah, A. E., Tinker, S. C., Samai, M.Mahon, B. E. (2020). Pregnancy outcomes among women receiving RVSVΔ-Zebov-GP Ebola vaccine during the Sierra Leone trial to introduce a vaccine against Ebola. Emerging Infectious Diseases, 26(3), 541-548. https://doi.org/10.3201/eid2603.191018

Publisher

Centers for Disease Control and Prevention (CDC)

Language

en

issn

1080-6040